MA50664A - Complexes d'antibiotiques peptidiques et leurs méthodes d'utilisation - Google Patents

Complexes d'antibiotiques peptidiques et leurs méthodes d'utilisation

Info

Publication number
MA50664A
MA50664A MA050664A MA50664A MA50664A MA 50664 A MA50664 A MA 50664A MA 050664 A MA050664 A MA 050664A MA 50664 A MA50664 A MA 50664A MA 50664 A MA50664 A MA 50664A
Authority
MA
Morocco
Prior art keywords
methods
peptidic
antibiotic complexes
complexes
peptidic antibiotic
Prior art date
Application number
MA050664A
Other languages
English (en)
Inventor
Christopher E Heise
Michael Friedrich Thomas Koehler
Jeremy Mark Murray
Peter Andrew Smith
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA50664A publication Critical patent/MA50664A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21089Signal peptidase I (3.4.21.89)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
MA050664A 2017-09-29 2018-09-26 Complexes d'antibiotiques peptidiques et leurs méthodes d'utilisation MA50664A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762566125P 2017-09-29 2017-09-29

Publications (1)

Publication Number Publication Date
MA50664A true MA50664A (fr) 2020-08-05

Family

ID=64744925

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050664A MA50664A (fr) 2017-09-29 2018-09-26 Complexes d'antibiotiques peptidiques et leurs méthodes d'utilisation

Country Status (6)

Country Link
US (1) US20200262869A1 (fr)
EP (1) EP3688028A2 (fr)
JP (1) JP2020536072A (fr)
CN (1) CN111386283A (fr)
MA (1) MA50664A (fr)
WO (1) WO2019067498A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6873993B2 (ja) 2015-11-20 2021-05-19 アールキューエックス ファーマシューティカルズ,インク. 大環状広域抗生物質
HRP20231497T1 (hr) * 2019-05-28 2024-03-01 F. Hoffmann-La Roche Ag Makrociklični antibiotici širokog spektra
WO2023245125A2 (fr) * 2022-06-15 2023-12-21 The Board Of Trustees Of The University Of Illinois Biosynthèse in vitro de divers peptides macrocycliques à base de pyridine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
CA2867448A1 (fr) * 2012-03-14 2013-09-19 Floyd E. Romesberg Analogues de l'arylomycine a spectre antibiotique large
CN103788176A (zh) * 2012-10-31 2014-05-14 上海来益生物药物研究开发中心有限责任公司 一种arylomycin类化合物及其制备方法和应用
JP6873993B2 (ja) * 2015-11-20 2021-05-19 アールキューエックス ファーマシューティカルズ,インク. 大環状広域抗生物質

Also Published As

Publication number Publication date
US20200262869A1 (en) 2020-08-20
WO2019067498A3 (fr) 2019-05-16
WO2019067498A2 (fr) 2019-04-04
CN111386283A (zh) 2020-07-07
EP3688028A2 (fr) 2020-08-05
JP2020536072A (ja) 2020-12-10

Similar Documents

Publication Publication Date Title
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
MA49288A (fr) Reactifs particulaires oligomères et leurs méthodes d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA44955A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA48595A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
MA49403A (fr) Compositions de pde5 et méthodes d'immunothérapie
MA44526A (fr) Oxystérols et leurs méthodes d'utilisation
MA42302A (fr) Lactames bicycliques et leurs méthodes d'utilisation
MA48579A (fr) Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
MA44524A (fr) Néoantigènes et leurs procédés d'utilisation
MA47499A (fr) Anticorps anti-tau et leurs procédés d'utilisation
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
MA42409A (fr) Oxystérols et leurs procédés d'utilisation
MA43385A (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
MA54851A (fr) Oxystérols et leurs procédés d'utilisation
MA46923A (fr) Compositions à base d'arni ciblant le gène serpina1 et leurs méthodes d'utilisation
MA50958A (fr) Anticorps anti-apoc3 et leurs méthodes d'utilisation
MA42118A (fr) Benzamides substitués et leurs méthodes d'utilisation
MA45602A (fr) Anticorps anti-apoc3 et leurs méthodes d'utilisation